Summary
Toremifene is currently being evaluated as a chemosensitizing agent in doxorubicin-resistant patients. Although concentrations of >2 μM reverse resistance in vitro, target concentrations required to reverse multidrug resistance (MDR) in vivo may be highly influenced by variables such as protein binding in serum. We examined the effects of high serum concentrations on the cellular accumulation of toremifene in an MDR MDA-MB-A-1 human breast-cancer cell line. We then examined the cellular accumulation of doxorubicin at various toremifene concentrations in 5%–100% serum. We also measured the concentrations of toremifene and its major metabolites in plasma specimens obtained from two patients receiving 360 mg/day for 5 days in a phase I study. Our results show that (1) high serum concentrations decrease toremifene accumulation, (2) toremifene concentrations of ≥2.5 μm enhance doxorubicin accumulation, and (3) patients achieve plasma toremifene concentrations of 10–15 μm following doses of 360 mg/day×5 days. Our findings suggest that in vivo toremifene concentrations well above those used to reverse resistance in vitro are required to overcome the effect of high serum-protein binding.
This is a preview of subscription content, log in via an institution to check access.
References
Baker WJ, Wiebe VJ, Koester SK, et al (1992) Toremifene enhances doxorubicin accumulation, inhibits protein kinase C (PKC) activity, increases PKC message, and enhances cytotoxicity in a tumor-bearing multidrug-resistant nude mouse model. Proc Am Soc Clin Oncol 11: 109
Chabner BA, Fojo A (1989) Multidrug resistance: P-glycoprotein and its allies, the elusive foes. J Natl Cancer Inst 81: 910–913
Cornwell MM, Gottesman MM, Pastan I (1986) Increased vinblastine binding to membrane vesicles from multidrug resistant KB cells. J Biol Chem 261: 7921–7928
DeGregorio MW, Carrera CJ, Klock JC, Wilbur JR (1982) Uptake and metabolism of daunorubicin by human leukemia cells. Cancer Chemother Pharmacol 10: 29–32
DeGregorio MW, Ford JM, Benz CC, Wiebe VJ (1989) Toremifene: pharmacologic and pharmacokinetic basis of reversing multidrug resistance. J Clin Oncol 7: 1359–1364
Gerlach JH, Kartner N, Bell DR, Ling V (1986) Multidrug resistance. Cancer Surv 5: 25–46
Gottesman MM, Pastan I (1989) Clinical trials of agents that reverse multidrug resistance. J Clin Oncol 7: 409–411
Holleran WM, Gharbo SA, DeGregorio MW (1987) Quantitation of toremifene and its major metabolites in human plasma following fluorescent activation. Anal Lett 20: 871–879
Inaba M, Nagashima K, Sakurai Y, et al (1984) Reversal of multidrug resistance by non-antitumor anthracycline analogs. Jpn J Cancer Res 75: 1049–1052
Lam PH (1984) Tamoxifen is a calmodulin antagonist in the activation of cAMP phosphodiesterase. Biochem Biophys Res Commun 118: 27–32
O'Brien CA, Liskamp RM, Solomon DH, et al (1986) Triphenylethylenes: a new class of protein kinase C inhibitors. J Natl Cancer Inst 76: 1243–1246
Ramu A, Shan TC, Glaubiger D (1983) Enhancement of doxorubicin and vinblastine sensitivity in anthracycline-resistant P-388 cells. Cancer Treat Rep 67: 895–899
Ramu A, Fuks Z, Gatt S, et al (1984) Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by perhexiline maleate. Cancer Res 44: 144–148
Sipilä Hanu, Näntö Veikko, Kangas Lauri, Anttila Markku, and Halme Tapio (1988) Binding of toremifene to human serum proteins. Pharmacology & Toxicology 63: 62–64
Tsuruo T, Iida H, Tsukagoshi S, et al (1982) Increased accumulation of vincristine and Adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res 42: 4730–4733
Wiebe VJ, Benz CC, Shemano I, Cadman TB, DeGregorio MW (1990) Pharmacokinetics of toremifene and its metabolites in patients with advanced breast cancer. Cancer Chemother Pharmacol 25: 247–251
Wiebe V, Koester S, DeGregorio M (1992) Toremifene and its metabolites enhance doxorubicin accumulation in estrogen receptor negative multidrug resistant human breast cancer cells. Invest New Drugs 10: 63–71
Zamora JM, Pearce HL, Beck WT (1988) Physical-chemical properties shared by compounds that modulate multiple drug resistance in human leukemia cells. Mol Pharmacol 33: 454–462
Author information
Authors and Affiliations
Additional information
This work was supported by grants from Orion Corporation-Farmos and the American Cancer Society (grant IRD 116)
Rights and permissions
About this article
Cite this article
Wurz, G.T., Emshoff, V.D., DeGregorio, M.W. et al. Targeting chemosensitizing doses of toremifene based on protein binding. Cancer Chemother. Pharmacol. 31, 412–414 (1993). https://doi.org/10.1007/BF00686157
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00686157